Effect of Olmesartan on left ventricular diastolic function in patients with chronic heart failure

Effect of Olmesartan on left ventricular diastolic function in patients with chronic heart failure - Olmesartan on diastolic function in patients with chronic heart failure

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011807

Enrollment

150

Registered

2013-09-19

Start date

2013-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failure

Interventions

Olmesartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with chronic heart failure who treated with ARBs except for olmesartan. 2. Left ventricular systolic dysfunction with ejection fraction<50% 3.Left ventricular diastolic dysfunction with ejection fraction>50%

Exclusion criteria

Exclusion criteria: 1. Hypotension (<90/50 mmHg) 2. Patients with acute coronary syndrome within 3-month, cerebral vascular disturbance, myocarditis, constrictive pericarditis and severe valvular disease. 3. Uncontrolled atrial fibrillation and flutter 4. Chronic kidney disease (Cr>3mg/dl) 5. Pateints with malignancy 6. Renal artery stenosis 7. Patient with pregnancy 8. Allergy of olmesartan 9. Patients who treated with ACEI

Design outcomes

Primary

Measure	Time frame
Left ventricular diastolic function 6 and 12 months after switching from other ARBs to olmesartan.	—

Countries

Japan

Contacts

Public ContactHidekazu Tanaka

Kobe University Graduate School of Medicine Division of Cardiovascular Medicine

tanakah@med.kobe-u.ac.jp078-382-5846

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026